Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer

Yoshihiro Kakeji, Eiji Oki, Akinori Egashira, Noriaki Sadanaga, Ikuo Takahashi, Masaru Morita, Yasunori Emi, Yoshihiko Maehara

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: This phase II study evaluated the toxicity and efficacy of a novel dosing schedule of docetaxel and S-1 as treatment for advanced gastric cancer. Methods: Patients with measurable advanced or recurrent gastric cancer and no prior exposure to the investigational drugs were treated with intravenous docetaxel 35 mg/m2 on days 1 and 15, and oral S-1 80 mg/m 2/day on days 1-14 every 4 weeks. The primary endpoint was objective response. Results: Thirty-five eligible patients were enrolled and received a total of 151 cycles of treatment (median 3, range 1-19). One complete response and 13 partial responses were observed, with an overall response rate of 40% (95% CI: 24-56%). Median progression-free survival and median overall survival times were 4.5 and 14.2 months, respectively. The most common grade 3-4 toxicities were neutropenia (23%) and leukocytopenia (15%). Conclusion: Biweekly docetaxel combined with S-1 is active in advanced or recurrent gastric cancer, and can be administered with proper management of adverse events in an outpatient clinic.

Original languageEnglish
Pages (from-to)49-52
Number of pages4
JournalOncology
Volume77
Issue number1
DOIs
Publication statusPublished - Jul 1 2009

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer'. Together they form a unique fingerprint.

  • Cite this

    Kakeji, Y., Oki, E., Egashira, A., Sadanaga, N., Takahashi, I., Morita, M., Emi, Y., & Maehara, Y. (2009). Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Oncology, 77(1), 49-52. https://doi.org/10.1159/000226111